In a crowded health-tech landscape, London Blood Tests Ltd is taking a stripped-back, execution-first approach, and it’s paying off. The UK-based private diagnostics company has built one of the broadest consumer blood-testing menus in the country, expanded a nationwide phlebotomy network, and turned steady profits, all without external investment.
“We focused on fundamentals: selection, access, and clarity,” said Owner and Founder, Gabriela Dabija. “That meant building the right partnerships, keeping overhead light, and earning trust test by test rather than chasing flash or fast money.”
The numbers back up the model. Two years of compound annual growth at 65% have set up a strong 2026.
“The pace of growth has been steady and disciplined, and we’ve done it without outside capital,” said Dabija. “Profitability matters to us as much as top line, so we track margins closely and invest where we see clear returns.”
What’s driving performance is a service built for reach and responsiveness. London Blood Tests offers more than 1,300 blood test types, among the widest selections in the UK, paired with customized panels tailored to individual needs. A network of more than 20 phlebotomists covers major UK cities, giving the company flexibility to meet customers where they are.
“We engineered the operation to meet people on their schedule,” said Dabija. “Breadth of tests, mobile phlebotomy coverage, and smart lab partnerships let us move quickly while keeping standards high.”
Revenue comes from three main streams: direct consumer bookings, partnerships with businesses, and the resale of medical products. The company runs lean, with a remote team and a mobile, asset-light operation that avoids premises costs.
Dabija said, “Our playbook is simple: rank well for what people actually need, be transparent on pricing and turnaround, and keep the buying journey smooth. We prefer durable channels over short-term spikes.”
Technology is increasingly central. London Blood Tests has rolled out a minimum viable product of its AI health report platform, which generates personalized reports for customers. These lay out results in plain language and include supplement suggestions and general wellness pointers. The goal is to turn complicated data into useful next steps, while encouraging follow-up with qualified healthcare professionals for diagnosis and treatment.
“We want results to feel understandable, not overwhelming. The AI report highlights what’s most relevant, offers practical wellness ideas, and prompts people to discuss findings with their clinician,” Dabija explained.
With foundation blocks in place, the growth plan is straightforward. More digital advertising, deeper social media engagement, and a larger phlebotomist network could each unlock incremental demand. The team also points to an international opportunity ready to go in Spain, giving the company a path to diversify revenue beyond the UK without heavy capital outlays.
“We’ve built the rails, now it’s about adding more trains,” said Dabija. “Expanding our practitioner network and turning on new channels should scale smoothly from the infrastructure we already have.”
The strategy reflects broader shifts in how consumers engage with healthcare. People want fast access to testing and a clear view of what the numbers mean. London Blood Tests is positioning itself as a broad catalog for specialized needs, paired with understandable reporting. The approach lowers friction for time-pressed consumers and supports more informed conversations with healthcare providers.
There’s also a disciplined business logic at work. Discounted lab fees, a remote-first structure, and careful channel selection stack the deck for profitability. The company’s reliance on organic SEO reduces acquisition costs, while the breadth of its catalog helps capture long-tail searches from consumers seeking specific markers or panels. Add in B2B partnerships and product resale, and the revenue mix balances one-off bookings with ongoing relationships.
Competition in diagnostics is active, and scaling quality alongside growth is always a test. But London Blood Tests’ playbook has room to run. If the team translates its UK traction into international momentum, it could become a case study in how focused operators scale healthcare services without heavy capital.
